{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:39:05Z","timestamp":1766180345564,"version":"build-2065373602"},"reference-count":30,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; To compare the effect of different dosages of subconjunctival bevacizumab with its topical administration on preventing the development of corneal neovascularization (CNV) in a rat model of corneal chemical injury. &lt;i&gt;Methods:&lt;\/i&gt; Neovascularization was induced by pressing a 2-mm diameter alkaline-coated applicator on the central cornea of the right eye of 50 anesthetized male rats. Immediately after cauterization, rats were divided randomly into 5 groups. Groups 1\u20134 received a subconjunctival injection of 0.02 ml of normal saline (control) or 1, 5 and 25 mg\/ml of bevacizumab, respectively. In the fifth group, topical bevacizumab was instilled daily for 7 consecutive days. After 7 days, digital photographs of the cornea were taken and the area of the neovascularized cornea was calculated. &lt;i&gt;Results:&lt;\/i&gt; Analysis of digital photographs showed that, compared with the controls, a single subconjunctival injection of at least 0.1 mg of bevacizumab (5 mg\/ml) \u2013 immediately after corneal cauterization \u2013 effectively decreased CNV after 7 days. Injection of 25 mg\/ml of bevacizumab in the fourth group increased the avascular area more than twofold, compared with the saline-treated group (32.2% compared with 15%, p &lt; 0.001). This difference between groups 4 and 2 was statistically significant (p = 0.04). Although topical delivery of 25 mg\/ml bevacizumab was effective to inhibit CNV (p = 0.004), the results were similar to those of the third group. Qualitative microscopic evaluation of the cornea was compatible with the gross findings, as bevacizumab-treated groups had less intense corneal vessel channels and inflammation. &lt;i&gt;Conclusion:&lt;\/i&gt; Both subconjunctival and topical bevacizumab can prevent CNV in rats.<\/jats:p>","DOI":"10.1159\/000322061","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T10:40:53Z","timestamp":1294656053000},"page":"50-54","source":"Crossref","is-referenced-by-count":22,"title":["Prevention of Corneal Neovascularization: Comparison of Different Doses of Subconjunctival Bevacizumab with Its Topical Form in Experimental Rats"],"prefix":"10.1159","volume":"46","author":[{"given":"Mohammad Naser","family":"Hashemian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Z-Mehrjardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasan","family":"Moghimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Tahvildari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda","family":"Mojazi-Amiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097%2F00055735-200108000-00002"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0039-6257%2898%2900035-6"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097%2F00003226-199811000-00008"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1006%2Fexer.1999.0790"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1600-0420.2004.00312.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007%2Fs10456-004-8272-2"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038%2Fnrd1381"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1600-0420.2007.01113.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1755-3768.2008.01312.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174%2F157339909787314121"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1755-3768.2008.01355.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1442-9071.2007.01572.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e31817786ad"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000224783"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e318159019f"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ajo.2007.11.003"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1755-3768.2008.01399.x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e31815cf67d"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00417-007-0684-4"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1442-9071.2009.02112.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ophtha.2008.02.013"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1600-0420.2007.01049.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097%2FICO.0b013e3180de1d0a"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109%2F02713688508999984"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136%2Fbjo.2006.107912"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00417-008-0976-3"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103%2F0301-4738.30702"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1006486207583"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ajo.2007.03.007"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00417-009-1099-1"}],"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322061","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:06:57Z","timestamp":1745435217000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000322061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,6,1]]},"published-print":{"date-parts":[[2011,6,16]]}},"URL":"https:\/\/doi.org\/10.1159\/000322061","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"type":"print","value":"0030-3747"},{"type":"electronic","value":"1423-0259"}],"subject":[],"published":{"date-parts":[[2011]]}}}